NCT02917096View on ClinicalTrials.gov

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2016

Primary Completion Date

April 16, 2020

Study Completion Date

August 31, 2023

Conditions

Primary MyelofibrosisSecondary Myelofibrosis

Interventions

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic HCT

DRUG

Fludarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

OTHER

Pharmacological Study

Correlative studies

DRUG

Ruxolitinib

Given PO

DRUG

Ruxolitinib Phosphate

Given PO

DRUG

Sirolimus

Given PO

DRUG

Tacrolimus

Given IV and PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02917096 - Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter